Skip to content Skip to footer
Subscribe Now
GRIN Therapeutics & Angelini Pharma
News

GRIN Therapeutics Collaborates with Angelini Pharma to Develop and Commercialize Radiprodil for Neurological Disorders

Shots:GRIN Therapeutics has granted Angelini Pharma exclusive rights to develop & market radiprodil worldwide, while GRIN will retain its rights in the US, Canada, & MexicoAs per the deal, GRIN will get $50M upfront & ~$520M in development, regulatory & sales milestones, with net sales-based tiered royalties & payments from future sublicenses outside…
16 hours ago

Read more

Weekly Snapshot

PharmaShots Weekly Snapshots (May 19, 2025 – May 23, 2025)   

This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilar, DigiHealth & Animal Health. Check out our full report below:   Apnimed Reports Topline P-III (SynAIRgy) Trial Data of AD109 for Obstructive Sleep Apnea (OSA) Read More: Apnimed Ionis Reveals Topline P-III (ESSENCE) Trial Data of Olezarsen for Moderate…
May 23, 2025

Read more

Genentech & Orionis
News

Genentech Collaborates with Orionis to Identify and Develop Molecular Glue Therapies for Cancer Targets

Shots:Genentech has entered into a multi-year collaboration with Orionis to discover small-molecule monovalent glue drugs for novel & difficult oncology targets using Orionis’ Allo-Glue platformAs per the deal, Orionis will receive $105M upfront & ~$2B in research, development, commercial, & sales milestones, with tiered royalties; Orionis will lead discovery & optimization, while Genentech…
May 22, 2025

Read more

Ramsoft & Therapixel
News

RamSoft and Therapixel Form a Commercial Partnership For an Integrated AI Breast Imaging Solution

Shots:RamSoft Inc. and Therapixel have entered into a commercial partnership to integrate Therapixel’s MammoScreen AI-powered breast imaging software into RamSoft’s PowerServer and OmegaAI platformsThis collaboration integrates Therapixel's MammoScreen, breast imaging AI, directly into RamSoft's platformsRecent studies showed that MammoScreen improves radiologist performance with 8% higher sensitivity, 2% higher specificity, and 24% faster…
May 21, 2025

Read more

Viz.ai, Sanofi & Regeneron
News

Viz.ai Enters a Multi-Year Partnership with Sanofi and Regeneron to Improve Management and Care of COPD

Shots:Viz.ai has entered into a multi-year collaboration with Sanofi & Regeneron to deploy and evaluate its AI-powered chronic obstructive pulmonary disease (COPD) workflow solutionSanofi, Regeneron, and Viz.ai collaborated on an AI-powered solution to improve care for high-risk COPD pts, focusing on how the Viz COPD module can enhance EHR workflows, access to care,…
May 21, 2025

Read more

Vant AI & Blueprint Medicines
News

VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery

Shots:VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needsAs per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…
May 21, 2025

Read more

23andMe
News

Regeneron to Acquire 23andMe Assets for $256M

Shots:Regeneron has entered into an asset purchase agreement with 23andMe for $256M, strengthening Regeneron’s genetics-guided research & drug development activitiesRegeneron to acquire key assets of 23andMe, incl. Personal Genome Service, Total Health & Research Services business lines, plus its Biobank & associated assets, with services continuing uninterrupted; closing is expected in Q3’2523andMe…
May 20, 2025

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]